There was a sizeable drop in the number of short positions at AC Immune SA during November (NASDAQ: ACIU). As of November 30, 336,100 shares were available for a short sale. This represented a decrease of 24.5% compared to the total 445,100 shares that were available on November 15. As a result, the days-to-cover ratio is currently at 4.3 days, calculated based on an average trading volume of 78,100 shares. This number was arrived at through the preceding calculation: At this time, 0.8% of the company’s shares are being traded on the short market to cover short positions.
The holdings of ACIU that are owned by a variety of hedge funds and institutional investors have recently been modified as a result of these changes. A new investment in AC Immune with a total value of $82,000 was made by Balyasny Asset Management LLC during the third quarter of 2018. During the third quarter, Kingsbury Capital Investment Advisors LLC was able to amass an additional 44.6% of the total number of AC Immune common stock shares. Kingsbury Capital Investment Advisors LLC now holds 27,291 shares and has acquired an additional 8,423 in the preceding quarter to bring its total number of shares to that. These shares are currently valued at $86,000 as of right now. During the second quarter, the percentage of AC Immune stock owned by UBS Group AG increased by 191.2%, bringing the total percentage to 100%. As a result, UBS Group AG had 36,000 fewer shares of the company’s stock in its possession three months ago than it does when each of those shares is currently worth $36,000. In the first three months of 2018, Handelsbanken Fonder AB increased its stake in AC Immune by investing 404,000 Swedish Krona. And lastly, during the first three months of this year, BlackRock Inc. expanded its holdings by 1.6% by purchasing additional AC Immune shares. After the deal’s completion, BlackRock Inc. gained ownership of an additional 4,685 shares, bringing its total number to 292,273, with a combined value of $1,169,000. There are currently, a total of 16.55% of the company’s shares owned by hedge funds and other types of institutional investors.
The coverage of AC Immune shares by a research note published on the website of StockNews.com began on October 23, a Sunday. They recommended that investors “hold” their shares in the company.
The NASDAQ ACIU began trading for $2.21 on Thursday when the market opened. The company has a beta value of 0.51 and a price-to-earnings ratio of -2.35, contributing to its market capitalization of $184.65 million. The price of a share of the company’s stock is currently trading at $2.71 for the moving average of the past 50 days, while the price is $3.00 for the moving average of the past 200 days. Before a year passed, a single AC Immune pill could be anywhere from $2.01 to $5.40.
The most recent earnings report for AC Immune, traded on the NASDAQ under the symbol ACIU, was published on Friday, October 28.
The actual earnings per share of the company for the quarter came in at $0.17, which was $0.07 more than the consensus estimate for their EPS, which was $0.24. In other words, the actual earnings per share were better than expected. In contrast to the 0.73 million dollars analysts from related companies predicted would be made in sales during the quarter, the actual amount made was 4.07 million dollars. The vast majority of market analysts hold that AC Immune will post a loss of $0.87 per share for the current fiscal year.
The biopharmaceutical company AC Immune SA is currently in the clinical stages of developing medications and diagnostic products to treat and cure neurodegenerative diseases caused by protein misfolding. These diseases include Alzheimer’s disease and Parkinson’s disease. The company is responsible for discovering, creating, and developing these medicines and products.